{"id":24618,"date":"2014-06-04T10:28:38","date_gmt":"2014-06-04T14:28:38","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=24618"},"modified":"2014-06-04T10:28:38","modified_gmt":"2014-06-04T14:28:38","slug":"teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618","title":{"rendered":"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 Israel-based <b>Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)<\/b> is pulling all stops in efforts to improve financial performance for the long-haul.<\/p>\n<p style=\"text-align: justify;\">In addition to internal adjustments, the company is also in the lookout for acquisition opportunities. And in the latest case the company announced the acquisition of Labrys Biologics, a startup that develops migraines treatments. Through the acquisition, Teva will add to its portfolio a drug candidate with the potential of generating up to $3 billion in peak sales.<\/p>\n<p style=\"text-align: justify;\">In a statement issued Tuesday, Teva said it has entered a definitive agreement to acquire the privately-held Labrys for about $825 million. Teva will make $200 million in upfront cash payment to Labrys and up to $625 million in contingent payment following achievement of certain milestones.<\/p>\n<p style=\"text-align: justify;\"><b>Center of attraction<\/b><\/p>\n<p style=\"text-align: justify;\">In making a bid for Labrys, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) sees great opportunity in LBR-101, which is a promising chronic migraine and episodic migraine treatment. LBR-101 was reported acquired from <b>Pfizer Inc (NYSE:PFE)<\/b> in 2012. The drug is currently in Phase IIb clinical trials.<\/p>\n<p style=\"text-align: justify;\">According to Teva officials, LBR-101 has not only shown compelling results in the previous trials, but also has a huge market potential. Teva&#8217;s Chief Scientific Officer and President of Global Research and Development, Michael Hayden, said more than 8.5 million people in the U.S., Europe and Japan are in need of chronic and episodic migraine treatment. And with LBR-101, Teva not only expects to improve the quality of life of the patients but also generate higher revenue from the drug.<\/p>\n<p style=\"text-align: justify;\">The closure of the deal between Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Labrys is subject to regulatory clearance and other conditions, the companies announced.<\/p>\n<p style=\"text-align: justify;\"><b>Organizational revamp<\/b><\/p>\n<p style=\"text-align: justify;\">Teva\u2019s move to ink a deal with Labrys comes just a day after the company announced its revamped organization that saw it trim the size of its executive committee. The company also unveiled a global quality-control chief.<\/p>\n<p style=\"text-align: justify;\">In the revamped organization, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) intends to bring its global generic operations under one unit.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 Israel-based Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is pulling all stops in efforts to improve financial performance for the long-haul. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":24620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[993,4029,2745,4028],"stock_ticker":[],"class_list":["post-24618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysepfe","tag-nyseteva","tag-pfizer-inc-nysepfe","tag-teva-pharmaceutical-industries-ltd-adr-nyseteva","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 Israel-based Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is pulling all stops in efforts to improve financial performance for the long-haul. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-04T14:28:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"312\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales\",\"datePublished\":\"2014-06-04T14:28:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg\",\"keywords\":[\"NYSE:PFE\",\"NYSE:TEVA\",\"Pfizer Inc (NYSE:PFE)\",\"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618\",\"name\":\"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg\",\"datePublished\":\"2014-06-04T14:28:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg\",\"width\":700,\"height\":312},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618","og_locale":"en_US","og_type":"article","og_title":"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales - Wall Street PR","og_description":"Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 Israel-based Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is pulling all stops in efforts to improve financial performance for the long-haul. [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-04T14:28:38+00:00","og_image":[{"width":700,"height":312,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales","datePublished":"2014-06-04T14:28:38+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg","keywords":["NYSE:PFE","NYSE:TEVA","Pfizer Inc (NYSE:PFE)","Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618","url":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618","name":"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg","datePublished":"2014-06-04T14:28:38+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Teva-Pharmaceutical-Industries-Limited1.jpg","width":700,"height":312},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/teva-pharmaceutical-industries-ltd-adr-nyseteva-acquires-drug-that-could-fetch-3-billion-in-sales-24618#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=24618"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/24620"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=24618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=24618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=24618"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=24618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}